4,000+
biopharma companies worldwide served by Cardinal Health Specialty Solutions
Advancing what’s possible for biopharma
Cardinal Health Specialty Solutions delivers configurable solutions to enhance your product’s success on the path to approval, launch and market adoption.
Solutions for Biopharma Success
Successfully launching and bringing a specialty drug to market has never been more complex. Whether you are in early-stage drug development or are on the verge of a launch, the journey from theory to breakthrough medicine can be daunting. And achieving the clinical milestones is only the first step.
To help your specialty drug reach its full potential, you need deep expertise at every stage. At Cardinal Health Specialty Solutions, we bring decades of experience in navigating regulatory pathways, delivering proven channel and distribution solutions, informing product decisions with HEOR, analyzing data to understand prescriber behavior, and removing barriers to care with proven access and patient support services. All to optimize your success on the way to approval and market adoption.
Explore our site to learn how we can help you advance what’s possible.
To help your specialty drug reach its full potential, you need deep expertise at every stage. At Cardinal Health Specialty Solutions, we bring decades of experience in navigating regulatory pathways, delivering proven channel and distribution solutions, informing product decisions with HEOR, analyzing data to understand prescriber behavior, and removing barriers to care with proven access and patient support services. All to optimize your success on the way to approval and market adoption.
Explore our site to learn how we can help you advance what’s possible.
Expert perspectives on bringing precision drugs to market
For proven insights on designing a successful commercial strategy for your precision therapy—from regulatory practices to logistics planning to patient support services—download our precision medicine white paper.
Possible barriers to biosimilar adoption
Our Chief Medical Officers, Dr. Bruce Feinberg and Dr. Chadi Nabhan, examine the hurdles impeding biosimilar adoption in oncology in the U.S. and propose possible solutions in this article in JAMA Oncology.
How do oncologists view precision medicine?
Download Oncology Insights, our latest research-based report, to access insights from more than 160 oncologists on the potential for precision medicine to reshape oncology care.